Stanford Cancer Institute

Ellie Guardino, MD, PhD, has been relentlessly pushing forward the science to advance breast cancer treatment. The former #Stanford oncologist who is battling advanced melanoma herself continues to fight for patients daily. Recently, Dr. Guardino received a surprise outpouring of love on her birthday by her family, friends, and patients on The Today Show. Happy birthday Dr. Guardino! You are very much loved! https://on.today.com/34UlZjl #breastcancerawareness @today

From Intern to Chief: A Tale of Partnerships and Persistence with a Vision for the Future Heather Wakelee, MD Tuesday, October 20, 2020 8:00 am 9:00 am Join us on Facebook Live!... Dr. Heather Wakelee is a Professor of Medicine in the Division of Oncology at @Stanford University and is the faculty director of the Stanford Cancer Clinical Trials Office. Dr. Wakelee has authored or co-authored over 200 medical articles on lung cancer and other thoracic malignancies and is involved in dozens of clinical trials related to lung cancer therapy and diagnostics. Her research focuses on many specific lung cancer subtypes defined by specific mutations in EGFR, ALK, ROS1, RET, BRAF, and others. She is also involved in trials of adjuvant therapy, immunotherapy, and anti-angiogenesis agents in addition to collaborations with colleagues focused on biomarkers and others focused on population science research. Dr. Wakelee is active in multiple national and international lung cancer research organizations including serving as a member of the Board of Directors of the International Association for the Study of Lung Cancer (IASLC), co-chair of the thoracic committee, and Stanford Principal Investigator for the Eastern Cooperative Oncology Group (ECOG-ACRIN), and as a Fellow of the American Society of Clinical Oncology (FASCO). #medicaloncology #stanfordcancer See more

What are viruses? And how do these tiny infectious particles, which straddle the line between life and non-life, multiply and spread to become global pandemics? More from Stanford Medicine: https://stanford.io/2T1tBv6

NCI's Cancer Moonshot Initiative, will establish a clinical, experimental, computational, and organizational framework to generate informative and accessible three-dimensional atlases of cancer transitions for a diverse set of tumor types. SCI members Jim Ford, MD, Michael Snyder, PhD, and Robert West MD, PhD, are contributing to this effort. The resulting tumor atlases should have a profound impact on our understanding of cancer biology and have the potential to improve cancer detection, prevention, and therapeutic discovery for better precision-medicine treatments of cancer patients and those at risk for cancer. #CancerMoonshot http://ow.ly/SjLx50Aj4Z3

Join Dean Lloyd Minor and special guest Bill Gates on Oct. 21 at 11:30 a.m. PT for a conversation about COVID-19 and the future of global health. http://stan.md/gates #StanfordMedLIVE

October, Breast Cancer Awareness Month, places a spotlight on the important scientific contributions made by the Breast Cancer Clinical Research Group at the SCI's Cancer Clinical Trials Office. Their efforts lead to an increased availability of clinical trials to patients in need and the results of these trials lead to advancements in care for current patients and future generations. A big thank you to our Breast Cancer Clinical Research Group. Keep up the good fight! #breastcancerawarenessmonth #pinktober2020

The SCI is proud to partner with the National LGBT Cancer Network! Out: The National Cancer Survey, the national survey specifically for LGBTQI+ cancer survivors. Take the survey & help inform cancer care for the estimated 81,000 LGBTQI+ people who are diagnosed with cancer every year. #outsurvey

Exciting news! The fencing has gone up around 300 Pasteur Drive in Palo Alto, marking the beginning of a six-year renovation and rebuilding project of the Stanford Hospital complex. The $1.2 billion project will include a new state of the art dedicated inpatient cancer hospital! https://med.stanford.edu//renewal-project-begins-at-stanfo

CAR-T are genetically modified immune cells recently approved for the treatment of childhood leukemia and lymphoma. This treatment is generally highly effective and not harmful, but sometimes comes with a risk: in rare cases, patients suffer from severe neurological disorders that can be life-threatening. SCI members Howard Chang, MD, PhD, Ansuman Satpathy, MD, PhD, and colleagues have succeeded in identifying one possible cause of this neurotoxicity. The target molecule of C...AR-T cells is present not only on the surface of cancer cells but also on the surface of pericytes, cells whose role is to protect the brain from external invasion. Their destruction by CAR-T cells could therefore explain why some patients suffer from neurotoxic effects. This discovery will hopefully allow scientists to modify the treatment to avoid the neurotoxic effect while maintaining its anti-tumor power. #chimericantigenreceptor https://www.cell.com/cell/fulltext/S0092-8674(20)31013-8